This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Big Stories For the Rest of 2014

Welcome Back to America

Pfizer (PFE) raised more than a few eyebrows when the New York based pharmaceuticals giant announced a deal to buy AstraZeneca (AZN) and invert its corporate home to the United Kingdom, which has a lower corporate tax rate.

While the move would be the first for a Down Jones Industrial Average conglomerate, it isn't a shock. Pharmaceutical giants have been moving to low-tax jurisdictions in droves through complex merger activity, and it is possible such tax-related strategies spread to other sectors.

However, if companies as prominent as Pfizer begin to try and shift their jurisdiction abroad, it might focus Washington on corporate tax reform. A more equitable U.S. and international tax system is a major topic of discussion in C-suites and on Wall Street but nothing has been done about it for years. At some point, Washington may react. Pfizer could be a turning point.

Taxes are one of the biggest stories facing U.S. corporations, which hold trillions of dollars in foreign profits abroad. A repatriation of those profits, instead of inversions to access them could drive a renaissance of corporate investment in the U.S.

>> Read More: Pfizer May Stay In Dow Even With Britain Move

-- Written by Antoine Gara in New York

6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BRK.B $143.89 0.00%
CMCSA $55.94 0.00%
KO $40.08 0.00%
TMUS $32.38 0.00%
VZ $48.56 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs